Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury : a pilot study
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved..
BACKGROUND AIMS: The potential of cell therapies to improve neurological function in subjects with spinal cord injury (SCI) is currently under investigation. In this context, the choice of cell type, dose, route and administration regimen are key factors. Mesenchymal stromal cells (MSCs) can be easily obtained, expanded and are suitable for autologous transplantation. Here we conducted a pilot study that evaluated safety, feasibility and potential efficacy of intralesional MSCs transplantation performed through image-guided percutaneous injection, in subjects with chronic complete SCI.
METHODS: Five subjects with chronic traumatic SCI (>6 months), at thoracic level, classified as American Spinal Cord Injury Association impairment scale (AIS) grade A, complete injury, were included. Somatosensory evoked potentials (SSEP), spinal magnetic resonance imaging (MRI) and urodynamics were assessed before and after treatment. Autologous MSCs were injected directly into the lesion site through percutaneous injection guided by computerized tomography (CT).
RESULTS: Tomography-guided percutaneous cell transplantation was a safe procedure without adverse effects. All subjects displayed improvements in spinal cord independence measure (SCIM) scores and functional independence measure (FIM), mainly due to improvements in bowel movements and regularity. Three subjects showed improved sensitivity to tactile stimulation. Two subjects improved AIS grade to B, incomplete injury, although this was sustained in only one of them during the study follow-up.
CONCLUSION: Autologous bone marrow MSC transplantation, performed through CT-guided percutaneous injection, was shown to be safe and feasible. Further studies are required to demonstrate efficacy of this therapeutic scheme.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Cytotherapy - 19(2017), 10 vom: 01. Okt., Seite 1189-1196 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Larocca, Ticiana Ferreira [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 05.03.2018 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcyt.2017.06.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM274346702 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM274346702 | ||
| 003 | DE-627 | ||
| 005 | 20231225003302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcyt.2017.06.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0914.xml |
| 035 | |a (DE-627)NLM274346702 | ||
| 035 | |a (NLM)28760352 | ||
| 035 | |a (PII)S1465-3249(17)30622-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Larocca, Ticiana Ferreira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury |b a pilot study |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2018 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND AIMS: The potential of cell therapies to improve neurological function in subjects with spinal cord injury (SCI) is currently under investigation. In this context, the choice of cell type, dose, route and administration regimen are key factors. Mesenchymal stromal cells (MSCs) can be easily obtained, expanded and are suitable for autologous transplantation. Here we conducted a pilot study that evaluated safety, feasibility and potential efficacy of intralesional MSCs transplantation performed through image-guided percutaneous injection, in subjects with chronic complete SCI | ||
| 520 | |a METHODS: Five subjects with chronic traumatic SCI (>6 months), at thoracic level, classified as American Spinal Cord Injury Association impairment scale (AIS) grade A, complete injury, were included. Somatosensory evoked potentials (SSEP), spinal magnetic resonance imaging (MRI) and urodynamics were assessed before and after treatment. Autologous MSCs were injected directly into the lesion site through percutaneous injection guided by computerized tomography (CT) | ||
| 520 | |a RESULTS: Tomography-guided percutaneous cell transplantation was a safe procedure without adverse effects. All subjects displayed improvements in spinal cord independence measure (SCIM) scores and functional independence measure (FIM), mainly due to improvements in bowel movements and regularity. Three subjects showed improved sensitivity to tactile stimulation. Two subjects improved AIS grade to B, incomplete injury, although this was sustained in only one of them during the study follow-up | ||
| 520 | |a CONCLUSION: Autologous bone marrow MSC transplantation, performed through CT-guided percutaneous injection, was shown to be safe and feasible. Further studies are required to demonstrate efficacy of this therapeutic scheme | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cell therapy | |
| 650 | 4 | |a clinical study | |
| 650 | 4 | |a mesenchymal stromal cells | |
| 650 | 4 | |a spinal cord injury | |
| 700 | 1 | |a Macêdo, Carolina Thé |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Bruno Solano de Freitas |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade-Souza, Yuri M |e verfasserin |4 aut | |
| 700 | 1 | |a Villarreal, Cristiane Flora |e verfasserin |4 aut | |
| 700 | 1 | |a Matos, André Costa |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Daniela Nascimento |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Kátia Nunes |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Clarissa Lima E Moura |e verfasserin |4 aut | |
| 700 | 1 | |a Paixão, Daniela da Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Bezerra, Milena da Rocha |e verfasserin |4 aut | |
| 700 | 1 | |a Alves, Rodrigo Leal |e verfasserin |4 aut | |
| 700 | 1 | |a Soares, Milena Botelho Pereira |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Ricardo Ribeiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytotherapy |d 1999 |g 19(2017), 10 vom: 01. Okt., Seite 1189-1196 |w (DE-627)NLM118333852 |x 1477-2566 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2017 |g number:10 |g day:01 |g month:10 |g pages:1189-1196 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcyt.2017.06.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2017 |e 10 |b 01 |c 10 |h 1189-1196 | ||